PRKDC and glioma: Overexpression of DNA-PK in 57.2% gliomas was associated with shorter survival of patients, and the inhibitor KU0060648 has been reported to significantly sensitize U87 and M059K GBM cells to TMZ.37 Another study discovered and characterized a novel DNA-PK inhibitor, nedisertib (M3814), and reported its potent radiosensitizing activity in a dose-dependent manner in the DNA-PK proficient MO59K GBM cell line where the enhancement ratio, calculated at 10% survival, ranged between 2.5 and 6.